In cancer, IMP2 serves as a pivotal player in multiple cancer types, including colorectal adenocarcinomas, breast adenocarcinomas, leukemia, lymphoma, hepatocellular carcinomas, lung adenocarcinomas, ovarian carcinomas, endometrial cancer, oral cancer, renal cell carcinoma, thyroid cancers, and glioblastoma. This evidence concerns the gene IGF2BP2 and thyroid gland carcinoma.